¿Existe un rol para el trasplante alogénico en el linfoma de Hodgkin en la era de los inhibidores de checkpoint?
ISSN 2250-8309 (versión en línea) - ISSN 0329-0379 (versión impresa)
pdf

Palabras clave

linfoma de Hodgkin, inhibidores de checkpoint, trasplante alogénico

Cómo citar

Perales, M., & Sánchez-Escamilla, M. (2019). ¿Existe un rol para el trasplante alogénico en el linfoma de Hodgkin en la era de los inhibidores de checkpoint?. Revista Hematología, 22(Extraordin), 13–22. Recuperado a partir de https://revistahematologia.com.ar/index.php/Revista/article/view/51

Resumen

El linfoma de Hodgkin (LH) afecta en Estados Unidos a unos 8500 nuevos pacientes cada año(1). Tiene una distribución binodal, con dos picos de máxima incidencia, adultos jóvenes de entre 15 y 30 años y adultos mayores de 55 años. A pesar de las altas tasas de remisión con la quimioterapia inicial, aproximadamente un 5-10% de los pacientes son primariamente refractarios y un 10-30% de ellos recaerá tras haber obtenido una remisión completa.

pdf

Citas

. Siegel RL, Jemal A, Wender RC, Gansler T, Ma J, Brawley OW. An Assessment of Progress in Cancer Control. 2018;00(00):1-11.
2. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 93(5):704-715.
3. Kusnierz-Glaz CR, Schlegel PG, Wong RM et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol. 1997;15(1):18-25.
4. Satwani P, Ahn KW, Carreras J et al. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015;50(11):1416-1423.
5. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862.
6. LaCasce AS, Gregory Bociek R, Sawas A et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40-48.
7. Eyre TA, Phillips EH, Linton KM et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. Br J Haematol. 2017;179(3):471-479.
8. Martino M, Festuccia M, Fedele R et al. Salvage treatment for relapsed/refractory hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. Expert Opin Biol Ther. 2015;2598(December):14712598.2015.1130821.
9. Bonthapally V, Wu E, Macalalad A et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. Curr Med Res Opin. 2015;31(5):993-1001.
10. Perrot A, Monjanel H, Bouabdallah R et al. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+Hodgkin lymphomas: A large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016;101(4):466-473.
11. Gopal AK, Chen R, Smith SE et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Bkood. 2015;125(8):1236-1244.
12. Armand P, Engert A, Younes A et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol. 2018;36(14):1428-1439.
13. Armand P, Engert A, Younes A et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):JCO.2017.76.079.
14. Merryman RW, Armand P. Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. Curr Hematol Malig Rep. 2017;12(1):44-50.
15. Perales MA, Sauter CS, Armand P. Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biol Blood Marrow Transplant. 2016;22(3):S9-S14.
16. Ghosh A, Politikos I, Perales M-A. Stop and go. Curr Opin Oncol. 2017;29(6):474-483.
17. Reddy NM, Perales MA. Stem cell transplantation in Hodgkin lymphoma. Hematol Oncol Clin North Am. 2014;28(6):1097-1112.
18. Perales MA, Ceberio I, Armand P et al. Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(6):971-983.
19. Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood. 2018:blood-2017-09-772673.
20. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol. 1996;14(2):572-578.
21. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14(4):1291-1296.
22. Sureda A, Robinson S, Canals C et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin’s Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455-462.
23. Sureda A, Canals C, Arranz R et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea. Haematologica. 2012;97(2):310-317.
24. Robinson SP, Sureda A, Canals C et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94(2):230-238.
25. Devetten MP, Hari PN, Carreras J et al. Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2009;15(1):109-117.
26. Martínez C, Gayoso J, Canals C et al. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marr. J Clin Oncol. 2017;35(30):3425-3432.
27. Castagna L, Bramanti S, Devillier R et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma: This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue. Bone Marrow Transplant. 2017;52(5):683-688.
28. Messer M, Steinzen A, Vervölgyi E et al. Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review. Leuk Lymphoma. 2014;55(2):296-306.
29. Sureda A, Bader P, Cesaro S et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2015. Bone Marrow Transplant. 2015;50(8):1037-1056.
30. Jethava Y, Guru Murthy GS, Hamadani M. Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? Hematol Oncol Stem Cell Ther. 2017;10(2):47-56.
31. Carella AM, Corradini P, Mussetti A, Ricardi U, Vitolo U, Viviani S. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. Ann Hematol. 2018:1301-1315.
32. Anderlini P, Champlin RE. Reduced Intensity Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Hodgkin Lymphoma: Where Do We Stand? Biol Blood Marrow Transplant. 2006;12(6):599-602.
33. Sureda A, Domenech E, Schmitz N, Dreger P. The role of allogeneic stem cell transplantation in Hodgkin’s lymphoma. Curr Treat Options Oncol. 2014;15(2):238-247.
34. Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood. 2018;131(15):blood-2017-09-772673.
35. Moskowitz CH. Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv. 2018;2(7):821-824.
36. Peggs KS. Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? Blood Adv. 2018;2(7):817-820.
37. Anderlini P, Saliba R, Acholonu S et al. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma. 2012;53(6):1239-1241.
38. Peggs KS, Kayani I, Edwards N et al. Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell–Depleted Allogeneic Transplantation for Hodgkin’s Lymphoma. J Clin Oncol. 2011;29(8):971-978.
39. Carlo-Stella C, Ricci F, Dalto S et al. Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers. Oncologist. 2015;20(3):323-328.
40. Theurich S, Wennhold K, Wedemeyer I et al. CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: Induction of clinical remission and cellular immunity. Transplantation. 2013;96(3):16-18.
41. Tsirigotis P, Danylesko I, Gkirkas K et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(10):1313-1317.
42. Anastasia A, Carlo-Stella C, Corradini P et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: A retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014;166(1):140-142.
43. Sala E, Crocchiolo R, Gandolfi S et al. Bendamustine Combined with Donor Lymphocytes Infusion in Hodgkin’s Lymphoma Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2014;20(9):1444-1447.
44. Roemer MGM, Advani RH, Ligon AH et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690-2697.
45. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol. 2008;26(1):677-704.
46. Michonneau D, Sagoo P, Breart B, Garcia Z, Celli S, Bousso P. The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation. Immunity. 2016;44(1):143-154.
47. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N Engl J Med. 2015;372(4):311-319.
48. Armand P, Shipp MA, Ribrag V et al. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733-3739.
49. Herbaux C, Gauthier J, Brice P et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129(18):2471-2478.
50. Younes A, Santoro A, Shipp M et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283-1294.
51. Merryman RW, Kim HT, Zinzani PL et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed / refractory lymphoma. Blood. 2017;129(10):1380-1389.
52. Sureda A, Pereira MIB, Dreger P. The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin’s lymphoma. Curr Opin Oncol. 2012;24(6):727-732.
53. Kanate AS, Mussetti A, Kharfan-Dabaja MA et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938-947.
54. Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: A systematic review and meta-analysis. Bone Marrow Transplant. 2016;51(4):521-528.
55. Raiola A, Dominietto A, Varaldo R et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplant. 2014;49(2):190-194.
56. Burroughs LM, O’Donnell P V., Sandmaier BM et al. Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279-1287.
57. Herbaux C, Merryman R, Devine S et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: Taming a necessary evil. Blood. 2018;132(1):9-16.
58. Haverkos BM, Abbott D, Hamadani M et al. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130(2):blood-2017-01-761346.
59. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.
60. Ijaz A, Khan AY, Malik SU et al. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors Before and After Allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
61. Anderlini P, Saliba R, Acholonu S et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: The updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93(2):257-264.
62. Kako S, Izutsu K, Kato K et al. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Am J Hematol. 2015;90(2):132-138.
63. Genadieva-Stavrik S, Boumendil A, Dreger P et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin’s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(12):2251-2257.
64. Gauthier J, Castagna L, Garnier F et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: A study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2017;52(5):689-696.
65. Martínez C, Gayoso J, Canals C et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for hodgkin lymphoma: A registry study of the lymphoma working party of the european society for blood and marr. J Clin Oncol. 2017;35(30):3425-3432.
66. Paviglianiti A, Maio KT, Rocha V et al. Outcomes of advanced Hodgkin lymphoma after umbilical cord blood transplantation: a Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party study. Biol Blood Marrow Transplant. 2018.
67. Mariotti J, Devillier R, Bramanti S et al. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Rela. Biol Blood Marrow Transplant. 2018;24(3):627-632.

Todo el material publicado en la revista Hematología (versión electrónica y versión impresa), será cedido a la Sociedad Argentina de Hematología. De conformidad con la ley de derecho de autor (ley 11723) se les enviara a los autores de cada trabajo aceptado formulario de cesión de derechos de autor que deberá ser firmado por todos los autores antes de la publicación. Los autores deberán retener una copia del original pues la revista, no acepta responsabilidad por daños o pérdidas del material enviado. Los autores deberán remitir una versión electrónica al correo: revista@sah.org.ar

Descargas

Los datos de descargas todavía no están disponibles.